Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. 2004

Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
Charleston Alcohol Research Center, Medical University of South Carolina, 67 President Street, PO Box 250861, Charleston, SC 29425, USA. antonr@musc.edu

BACKGROUND This clinical laboratory study evaluated how the timing of drinking and subjective responses to alcohol are effected by the opioid antagonist naltrexone. METHODS Forty non-treatment seeking alcoholics were randomly assigned to treatment with 50 mg naltrexone or matching placebo for 7 days. On day 7, they were administered an "initial drink" of alcohol (blood alcohol levels of between 20 and 30 mg%) in a bar-like setting. In a random fashion, half of the subjects in each group (naltrexone and placebo) had either immediate or delayed (40 min) access to up to 8 additional mini-drinks over a 2-h period. In the delayed group subjective reactions to alcohol were measured prior to access to more drinks. RESULTS In the immediate access condition, subjects had similar drinking patterns, irrespective of whether they were taking naltrexone or placebo. However, in the delayed condition, naltrexone-treated subjects consumed fewer drinks and had a slower progression of drinking. There was a positive relationship between alcohol-induced stimulation and the number of drinks consumed in the placebo subjects but a negative correlation in the naltrexone subjects. CONCLUSIONS These data suggest that the effectiveness of naltrexone on alcohol consumption may be somewhat dependent on pattern of consumption. Since naltrexone seems to disrupt the connection between alcohol-induced stimulation and further alcohol consumption, there may be a time-critical period between drinks necessary for alcoholics to benefit from its effects. These findings are consistent with clinical trial data that suggest a potential synergistic effect between relapse prevention therapies and opiate antagonist pharmacotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009271 Naltrexone Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. Antaxone,Celupan,EN-1639A,Nalorex,Naltrexone Hydrochloride,Nemexin,ReVia,Trexan,EN 1639A,EN1639A
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D002492 Central Nervous System Depressants A very loosely defined group of drugs that tend to reduce the activity of the central nervous system. The major groups included here are ethyl alcohol, anesthetics, hypnotics and sedatives, narcotics, and tranquilizing agents (antipsychotics and antianxiety agents). CNS Depressants,Depressants, CNS
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000428 Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking. Alcohol Consumption,Alcohol Intake,Drinking, Alcohol,Alcohol Drinking Habits,Alcohol Drinking Habit,Alcohol Intakes,Consumption, Alcohol,Drinking Habit, Alcohol,Habit, Alcohol Drinking,Habits, Alcohol Drinking,Intake, Alcohol

Related Publications

Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
February 2007, Alcoholism, clinical and experimental research,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
November 2008, Alcoholism, clinical and experimental research,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
September 2012, Psychopharmacology,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
September 2015, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
January 1991, Psychopharmacology,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
January 1995, The Journal of clinical psychiatry,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
June 2019, Experimental and clinical psychopharmacology,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
January 2009, Journal of substance abuse treatment,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
August 2015, Drug and alcohol dependence,
Raymond F Anton, and David J Drobes, and Konstantin Voronin, and Ramon Durazo-Avizu, and Darlene Moak
January 1988, Alcohol (Fayetteville, N.Y.),
Copied contents to your clipboard!